Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 7/2018

01.07.2018 | Sleep (M Thorpy and M Billiard, Section Editors)

The Sleep Disorder in Anti-lgLON5 Disease

verfasst von: Carles Gaig, Alex Iranzo, Joan Santamaria, Francesc Graus

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review the clinical and polysomnographic features of the sleep disorder occurring in the recently described anti-IgLON5 disease. The hallmark of the disease is the presence of antibodies against IgLON5, a neural cell adhesion molecule of unknown function. The disease presents a robust HLA association, and the neuropathological examination shows a novel neuronal tauopathy with predominant hypothalamic and brainstem involvement.

Recent Findings

Most patients (> 80%) present sleep-related vocalizations with movements and behaviors and sleep-disordered breathing. Polysomnographic studies show (1) a complex NREM sleep parasomnia at sleep initiation characterized by undifferentiated NREM or poorly structured N2 sleep with sleep-talking or mumbling, and simple or finalistic movements followed by normal periods of N3 or N2 NREM sleep, (2) REM sleep behavior disorder (RBD), and (3) obstructive sleep apnea with stridor. The last two features appear mainly in periods where NREM sleep normalizes.

Summary

Identification of the anti-IgLON5 sleep disorder is important to suspect the disease. The combination of abnormal NREM sleep initiation, followed by normal periods of NREM sleep and RBD, represents a novel parasomnia.
Literatur
1.
Zurück zum Zitat •• Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86. In this paper the disease is identified and described for first time. CrossRefPubMedPubMedCentral •• Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86. In this paper the disease is identified and described for first time. CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat •• Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43. The clinical presentation of the disease is described in detail in a series of 22 patients. CrossRefPubMedPubMedCentral •• Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43. The clinical presentation of the disease is described in detail in a series of 22 patients. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat •• Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531–43. The neuropathological features of the disease are described in detail and neuropathological criteria for anti-IgLON5 disease are defined. CrossRefPubMedPubMedCentral •• Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531–43. The neuropathological features of the disease are described in detail and neuropathological criteria for anti-IgLON5 disease are defined. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87:521–8.CrossRefPubMedPubMedCentral van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87:521–8.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64.CrossRefPubMedPubMedCentral Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat • Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590. Report of the first patient after the initial description of the disease. CrossRefPubMed • Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590. Report of the first patient after the initial description of the disease. CrossRefPubMed
7.
Zurück zum Zitat Bahtz R, Teegen B, Borowski K, Probst C, Blöcker IM, Fechner K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.CrossRef Bahtz R, Teegen B, Borowski K, Probst C, Blöcker IM, Fechner K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.CrossRef
8.
Zurück zum Zitat Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e302.CrossRefPubMedPubMedCentral Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e302.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.CrossRefPubMed Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.CrossRefPubMed
10.
Zurück zum Zitat Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e383.CrossRefPubMedPubMedCentral Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e383.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Haitao R, Huiqin L, Tao Q, Xunzhe Y, Xiaoqiu S, Wei L, et al. Autoimmune encephalitis associated with vitiligo? J Neuroimmunol. 2017;310:14–6.CrossRefPubMed Haitao R, Huiqin L, Tao Q, Xunzhe Y, Xiaoqiu S, Wei L, et al. Autoimmune encephalitis associated with vitiligo? J Neuroimmunol. 2017;310:14–6.CrossRefPubMed
12.
Zurück zum Zitat Wenninger S. Expanding the clinical Spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337–9.CrossRefPubMed Wenninger S. Expanding the clinical Spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337–9.CrossRefPubMed
13.
Zurück zum Zitat • Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. Description of another series of 20 patients with antibodies against IgLON5. CrossRefPubMedPubMedCentral • Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. Description of another series of 20 patients with antibodies against IgLON5. CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat • Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136. Additional description of a patient with anti-IgLON5 antibodies and progressive disease course. CrossRefPubMedPubMedCentral • Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136. Additional description of a patient with anti-IgLON5 antibodies and progressive disease course. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat • Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762–4. Description of a patient with atypical clinical features. CrossRefPubMed • Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762–4. Description of a patient with atypical clinical features. CrossRefPubMed
16.
Zurück zum Zitat Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30(Suppl 1):710. Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30(Suppl 1):710.
17.
Zurück zum Zitat Iranzo A, Santamaría J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep. 2005;28:203–6.CrossRefPubMed Iranzo A, Santamaría J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep. 2005;28:203–6.CrossRefPubMed
18.
Zurück zum Zitat Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 2006;7:175–83.CrossRefPubMed Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 2006;7:175–83.CrossRefPubMed
19.
Zurück zum Zitat Mahowald MW, Schenck CH. Status dissociatus: a perspective on states of being. Sleep. 1991;14:69–79.CrossRefPubMed Mahowald MW, Schenck CH. Status dissociatus: a perspective on states of being. Sleep. 1991;14:69–79.CrossRefPubMed
20.
Zurück zum Zitat Montagna P, Lugaresi E. Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol. 2002;113:552–60.CrossRefPubMed Montagna P, Lugaresi E. Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol. 2002;113:552–60.CrossRefPubMed
21.
Zurück zum Zitat Gaig C, Iranzo A, Santamarí J, Dalmau J, Graus F. Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?—Authors’ reply. Lancet Neurol. 2014;13:864–5.CrossRefPubMed Gaig C, Iranzo A, Santamarí J, Dalmau J, Graus F. Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?—Authors’ reply. Lancet Neurol. 2014;13:864–5.CrossRefPubMed
22.
Zurück zum Zitat Baiardi S, Provini F, Avoni P, Pasquinelli M, Liguori R. Immunotherapy of oneiric stupor in Morvan syndrome: efficacy documented by actigraphy. Neurology. 2015;84:2457–9.CrossRefPubMed Baiardi S, Provini F, Avoni P, Pasquinelli M, Liguori R. Immunotherapy of oneiric stupor in Morvan syndrome: efficacy documented by actigraphy. Neurology. 2015;84:2457–9.CrossRefPubMed
23.
Zurück zum Zitat Dumitrascu O, Schenck CH, Applebee G, Attarian H. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14:1217–20.CrossRefPubMed Dumitrascu O, Schenck CH, Applebee G, Attarian H. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14:1217–20.CrossRefPubMed
24.
Zurück zum Zitat Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer’s Dis. 2017;59:13–20.CrossRef Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer’s Dis. 2017;59:13–20.CrossRef
25.
Zurück zum Zitat Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.CrossRefPubMedPubMedCentral Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Sleep Disorder in Anti-lgLON5 Disease
verfasst von
Carles Gaig
Alex Iranzo
Joan Santamaria
Francesc Graus
Publikationsdatum
01.07.2018
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 7/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0848-0

Weitere Artikel der Ausgabe 7/2018

Current Neurology and Neuroscience Reports 7/2018 Zur Ausgabe

Behavior (H S Kirshner, Section Editor)

Thalamic Lesions and Aphasia or Neglect

Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Behçet’s Syndrome and Nervous System Involvement

Sleep (M Thorpy and M Billiard, Section Editors)

Narcolepsy Associated with Pandemrix Vaccine

Headache (R Halker, Section Editor)

Women and Migraine: the Role of Hormones

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.